Janus Henderson Investors US LLC has recently announced that it has increased stake in Olema Pharmaceuticals Inc. (NASDAQ:OLMA) by 2.27%. After grabbing 3.4 million shares, the institutional investor is now in possession of 75554.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.40% having worth around $9.75 million. Moreover, The Vanguard Group, Inc. increased its share by 61160.0 to have a control over 1.46 million shares. And Kynam Capital Management LP raised its holdings to 1.15 million shares by acquiring 1.4 million shares or 3.46% of the stake.
Olema Pharmaceuticals Inc. (OLMA) concluded trading on 01/12/23 at a closing price of $4.01, with 0.79 million shares of worth about $3.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.83% during that period and on Thursday the price saw a gain of about 2.30%. Currently the company’s common shares owned by public are about 40.04M shares, out of which, 37.70M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the OLMA stock and their offered price forecasts bring an average price target of $13.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $16.00 and could fall to a lowest price of $10.00. The stock’s current price level is 69.74% above of average price target set by the analysts, while a rise to estimated low would result in gain of 59.9% for the stock. However, touching the estimated high of $16.00 would mean a gain of 74.94% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 9 times over the past 12 months. They bought 270,504 shares in 7 of the transactions. In 2 selling transactions, insiders dumped 10,504 shares.
Vanguard Total Stock Market Index, Janus Henderson Global Life Scien, and Janus Henderson Capital Funds Plc are the top 3 mutual funds which are holding stakes in Olema Pharmaceuticals Inc. Vanguard Total Stock Market Index is currently holding 1.01 million shares of worth totaling $2.89 million. The company recently came buying 0.0 shares which brought its stake up to 2.49% of the company’s outstanding shares. Janus Henderson Global Life Scien sold 7775.0 shares, after which its hold over company’s outstanding shares shrunk to 1.83%, leaving 0.74 million shares with the mutual fund that have a worth of about $2.13 million. Janus Henderson Capital Funds Plc, after selling 0.65 million shares, have now control over 1.60% of the stake in the company. It holds 229.0 shares of worth $1.86 million.
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) started trading at $3.75, below -$0.17 from concluding price of the previous day. However, the stock later moved at a day high price of 4.0500, or with a gain of 2.30%. Stock saw a price change of 45.82% in past 5 days and over the past one month there was a price change of 68.49%. Year-to-date (YTD), OLMA shares are showing a performance of 63.67% which decreased to -45.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.00 but also hit the highest price of $7.41 during that period. The average intraday trading volume for Olema Pharmaceuticals Inc. shares is 121.90K. The stock is currently trading 51.66% above its 20-day simple moving average (SMA20), while that difference is up 41.10% for SMA50 and it goes to 16.17% higher than SMA200.
Janus Henderson Investors US LLC acquired 3.4 million shares of Olema Pharmaceuticals Inc. having value of about $9.75 million. Data submitted at the U.S SEC by Janus Henderson Investors US LLC revealed that the firm now holds 75554.0 shares in the company valued at close to $302971.54, or have control over 2.27% stake in the company. Olema Pharmaceuticals Inc. (NASDAQ: OLMA) currently have 40.04M outstanding shares and institutions hold larger chunk of about 84.60% of that. Holding of mutual funds in the company is about 25.31% while other institutional holders and individual stake holders have control over 63.66% and 15.85% of the stake respectively.
The stock has a current market capitalization of $156.59M. It has posted earnings per share of -$2.51 in the same period. It has Quick Ratio of 17.90 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OLMA, volatility over the week remained 14.35% while standing at 11.18% over the month.
Analysts are in expectations that Olema Pharmaceuticals Inc. (OLMA) stock would likely to be making an EPS of -$0.77 in the current quarter, while forecast for next quarter EPS is -$0.76 and it is -$3.23 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.9 which is -$0.68 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.45 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -188.80% while it is estimated to decrease by -13.50% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Canaccord Genuity on July 06, 2022 offering a Buy rating for the stock and assigned a target price of $16 to it. Coverage by H.C. Wainwright stated Olema Pharmaceuticals Inc. (OLMA) stock as a Buy in their note to investors on June 09, 2022, suggesting a price target of $12 for the stock. Stock get an Overweight rating from JP Morgan on December 14, 2020.